MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/xce.0000000000000334

Медицинская библиотека · Cardiovascular endocrinology & metabolism · 2025

BRIDGE-DS study: evaluating the effectiveness and safety of dapagliflozin/sitagliptin combination in type 2 diabetes mellitus patients with heart failure.

Kumar Kandanat Purushothaman Nair Suresh, Variam Manikandan Thiruvanath, S Bala Vignesh, Nath Kshitiz, Goyal Kailash Kumar, Beswal Gaurav, Arun Prashanth, Narayan Kiran, Kumar S P Sathish, Ravindranath V, Tripathy Nishant, Kalra Bharat Kumar, Ray Pranabes, Garg Pooja, Laul Anil, Dhand Sunil, Kamat Sajal, Kesarkar Rohan Narayan, Prasad Ashish, Pednekar Abhijit

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.

AIM: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.

METHODS

This was a retrospective, multicenter, observational study that included data from 168 T2DM patients with HF receiving treatment with FDC D/S. Outcome parameters included glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), hypertension, N-terminal pro-B-type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR), and adverse events.

RESULTS

The mean age of the patients was 55.5 ± 10.5 years. Most patients had comorbidities such as hypertension (86.3%) and dyslipidemia (75%), with more than 53% being obese. A significant (P < 0.0001) reduction was observed in HbA1c, FPG, PPG, and NT-proBNP levels, and in systolic blood pressure (SBP) and diastolic blood pressure (DBP) after 3 months of treatment with FDC D/S, while a significant (P < 0.0001) increase was observed in ejection fraction and eGFR, indicating improved glycemic control and heart function. Urinary tract infections (29.8%), dehydration (17.9%), hypoglycemia (14.9%), and genital mycotic infection (6.6%) were the common adverse events encountered with FDC D/S.

CONCLUSION

FDC D/S enhances glycemic control in T2DM patients with HF, leading to reductions in HbA1c, FPG, PPG, and cardiovascular risk factors such as NT-proBNP, SBP, and DBP, while also improving eGFR. The FDC D/S was generally well-tolerated, making it an effective and convenient treatment option.

Для цитирования: Kumar Kandanat Purushothaman Nair Suresh, Variam Manikandan Thiruvanath, S Bala Vignesh, Nath Kshitiz, Goyal Kailash Kumar, Beswal Gaurav, Arun Prashanth, Narayan Kiran, Kumar S P Sathish, Ravindranath V, Tripathy Nishant, Kalra Bharat Kumar, Ray Pranabes, Garg Pooja, Laul Anil, Dhand Sunil, Kamat Sajal, Kesarkar Rohan Narayan, Prasad Ashish, Pednekar Abhijit. BRIDGE-DS study: evaluating the effectiveness and safety of dapagliflozin/sitagliptin combination in type 2 diabetes mellitus patients with heart failure.. Cardiovascular endocrinology & metabolism. 2025. DOI: 10.1097/xce.0000000000000334.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.